LYRA · Lyra Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $398.0K | $1.53M | $1.56M | $1.36M | $285.0K | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $18.41M | $43.77M | $48.03M | $38.80M | $29.69M | $12.52M |
| SG&A | $11.54M | $18.50M | $19.06M | $17.56M | $14.21M | $9.69M |
| Total Operating Expenses | $31.42M | $97.88M | $68.68M | $57.67M | $43.90M | $22.21M |
| D&A | $459.0K | $471.0K | $278.0K | $1.07M | $1.00M | $95.0K |
| Operating Income | ($31.02M) | ($96.35M) | ($67.12M) | ($56.31M) | ($43.62M) | ($22.21M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $11.0K | $39.0K | $59.0K | $13.0K | $0 | $0 |
| Net Income | ($28.92M) | ($93.44M) | ($62.68M) | ($55.28M) | ($43.51M) | ($22.13M) |
| EPS - Basic | ($18.62) | ($71.50) | ($63.00) | ($167.50) | - | - |
| EPS - Diluted | ($18.62) | ($71.50) | ($63.00) | ($91.50) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $15.89M | $40.58M | $22.35M | $32.55M | $45.75M | $74.59M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $663.0K | $1.18M | $3.13M | $2.62M | $3.13M | $922.0K |
| Current Assets | $16.27M | $43.02M | $104.82M | $100.83M | $47.92M | $75.92M |
| Total Assets | $36.11M | $66.35M | $142.60M | $109.97M | $54.87M | $80.83M |
| Current Liabilities | $9.52M | $12.63M | $19.60M | $14.47M | $18.25M | $4.88M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $46.83M | $54.75M | $53.18M | $29.21M | $20.55M | $6.34M |
| Stockholders' Equity | ($10.72M) | $11.59M | $89.42M | $80.75M | $34.32M | $74.49M |
| Retained Earnings | ($433.71M) | ($404.79M) | ($311.36M) | ($248.68M) | ($193.40M) | ($149.88M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($28.86M) | ($70.01M) | ($63.30M) | ($43.38M) | ($25.82M) | ($21.14M) |
| Investing Cash Flow | ($98.0K) | $80.31M | ($12.58M) | ($65.01M) | ($3.38M) | ($1.77M) |
| Financing Cash Flow | $4.27M | $8.53M | $65.69M | $96.26M | $359.0K | $87.70M |
| CapEx | $116.0K | $2.34M | $1.05M | $164.0K | $3.38M | $1.77M |
| Free Cash Flow | ($28.98M) | ($72.35M) | ($64.35M) | ($43.55M) | ($29.20M) | ($22.92M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -7794.5% | -6280.8% | -4308.1% | -4131.0% | -15303.5% | - |
| EBITDA margin | -7679.1% | -6250.1% | -4290.2% | -4052.8% | -14952.3% | - |
| Net margin | -7266.1% | -6090.9% | -4023.1% | -4055.6% | -15267.7% | - |
| Free cash flow margin | -7280.2% | -4716.4% | -4130.4% | -3195.1% | -10247.4% | - |
| FCF / Net income | 1.00 | 0.77 | 1.03 | 0.79 | 0.67 | 1.04 |
| R&D / Revenue | 4625.9% | 2853.1% | 3082.7% | 2846.4% | 10418.9% | - |
| SG&A / Revenue | 2899.5% | 1206.1% | 1223.2% | 1288.0% | 4984.6% | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -80.1% | -140.8% | -44.0% | -50.3% | -79.3% | -27.4% |
| Return on equity | 269.8% | -805.9% | -70.1% | -68.5% | -126.8% | -29.7% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 1.71 | 3.41 | 5.35 | 6.97 | 2.63 | 15.54 |
| Quick ratio | 1.71 | 3.41 | 5.35 | 6.97 | 2.63 | 15.54 |
| Cash ratio | 1.67 | 3.21 | 1.14 | 2.25 | 2.51 | 15.27 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | -3.37 | 5.72 | 1.59 | 1.36 | 1.60 | 1.09 |
| Liabilities / Assets | 1.30 | 0.83 | 0.37 | 0.27 | 0.37 | 0.08 |
| Efficiency | ||||||
| Asset turnover | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | 58.0x | 145.9x | 25.2x | - | - |
| P / S | 12.0x | 438.1x | 8375.3x | 1495.8x | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -74.1% | -1.5% | 14.3% | 378.2% | - | - |
| Revenue CAGR (3y) | -33.7% | 75.3% | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 67.8% | -43.5% | -19.2% | -29.1% | -96.4% | - |
| Net income growth (YoY) | 69.0% | -49.1% | -13.4% | -27.0% | -96.7% | - |
| EPS growth (YoY) | 74.0% | -13.5% | 31.1% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 60.0% | -12.4% | -47.8% | -49.1% | -27.4% | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | - | -87.0% | 10.7% | 135.3% | -53.9% | - |
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-12.79
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- -Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing Lyra Therapeutics against the 5 most active filers in the same SIC group.